Related by context. All words. (Click for frequent words.) 84 mg/m2 76 mcg kg 73 #mg/m# [002] 72 mg m² 72 mg/m2/day 70 #mg/m# [001] 70 mg kg 67 mg QD 65 mg/m2 IV 65 mg TID 64 Q2W 64 μg dose 64 mg 64 mg d 64 mcg 63 administered subcutaneously 63 mg BID 63 q#h 63 mg/m2 administered 63 mg orally 63 Peg IFN 63 fluorouracil 63 mitoxantrone 63 ug kg 63 mg qd 62 mg/m2 dose 62 mg kg dose 62 μg 62 docetaxel 62 μg kg 62 piperacillin tazobactam 61 #mg/kg [002] 61 4mg/kg 61 nab paclitaxel 61 mg q8h 61 #mg QD [002] 61 8mg/kg 60 mcg BID 60 dosing cohorts 60 FOLFOX 60 mg dose 60 lopinavir r 60 intramuscularly 60 q8h 60 continuous intravenous infusion 60 carboplatin 60 mg eq 60 ascending dose 60 febrile neutropenia 59 cyclophosphamide 59 mcg dose 59 #mg q8h 59 comparator arm 59 peginterferon alfa 2a 59 FOLFOX4 alone 59 intravenous REOLYSIN 59 intermittent dosing 59 mg/# hr 59 CIMZIA TM 59 IU ml 59 mcg albinterferon alfa 2b 59 microgram kg 59 FOLFIRI 59 kBq kg 59 mCi 59 titrated 59 mg administered orally 59 FOLPI 59 mg kg hr 59 biochemical relapse 59 mcg mL 59 #mg BID [001] 58 dose regimens 58 doxorubicin cyclophosphamide 58 saline placebo 58 Median survival 58 5-FU/LV 58 administered orally 58 mitomycin 58 pegylated interferon alfa 2a 58 ascending doses 58 BEACOPP 58 mCi m 2 58 subcutaneous doses 58 docetaxel chemotherapy 58 peg IFN 58 lopinavir r arm 58 mCi kg 58 plus prednisone 58 dose cohorts 58 estramustine 58 mg subcutaneously 58 intravenous infusion 58 interferon alfa 58 vinorelbine 58 dacarbazine 58 Locteron administered 58 #mg QD [001] 57 IV bolus 57 pegylated interferon alfa 2b 57 oral prednisone 57 mg subcutaneous injection 57 PEG IFN 57 carboplatin paclitaxel 57 alfa 2a 57 telaprevir dosed 57 oral allopurinol 57 plus ribavirin 57 atazanavir ritonavir 57 fluorouracil leucovorin 57 QD dosing 57 evaluable 57 Folfox 57 #mg BID [003] 57 subcutaneously 57 melphalan 57 progression TTP 57 REYATAZ r 57 median PFS 57 cytarabine daunorubicin 57 dose limiting toxicities 57 gemcitabine 57 mg RDEA# 57 mcg doses 57 etoposide 57 achieved PASI 56 PREZISTA r 56 APTIVUS r 56 ribavirin RBV 56 achieved ACR# 56 #mg [003] 56 LEXIVA r 56 adalimumab 56 rapid virologic response 56 lispro 56 induction regimen 56 daunorubicin 56 log# copies mL 56 adriamycin 56 dosing cohort 56 mcg Albuferon 56 FOLFOX4 56 dose cohort 56 LPV r 56 standard chemotherapy regimen 56 plus methotrexate 56 mg ustekinumab 56 ARIKACE 56 chlorambucil 56 Pegasys ® 56 ritonavir boosted 56 abacavir lamivudine 56 mg/# mg [002] 56 monotherapy 56 mg simvastatin 56 mg kg IV 56 administered intravenously 56 5 Fluorouracil 56 #mg/day [001] 55 n = 55 idarubicin 55 intravenous bolus 55 refractory NSCLC 55 mg/# hours 55 treatment naive genotype 55 pg mL 55 tolerated dose MTD 55 injected subcutaneously 55 interferon alfa 2a 55 3mg/kg 55 peginterferon alfa 2a Pegasys 55 VELCADE melphalan 55 docetaxel Taxotere R 55 placebo p = 55 cGy 55 CHOP chemotherapy 55 certolizumab 55 evaluable patients 55 dose escalation 55 Gy fractions 55 timepoints 55 clodronate 55 LANTUS R 55 subcutaneous injections 55 active comparator 55 azathioprine 55 mg doses 55 FOLFOX6 55 g dL 55 mitoxantrone plus 55 decitabine 55 Capecitabine 55 relapsed refractory multiple myeloma 55 REYATAZ r arm 55 severe neutropenia 55 placebo intravenously 55 Tarceva TM 55 intravenous doses 55 #mg/day [002] 55 DLTs 55 Pegasys plus Copegus 55 cyclophosphamide methotrexate 55 #mg BID [002] 55 epirubicin 55 RGT arm 55 log# 55 ALVESCO 55 #ug [001] 55 vandetanib 55 μmol L 55 3mg 54 #μg [001] 54 bortezomib 54 PREZISTA ritonavir 54 telaprevir dosing 54 hypokalemia 54 8mg 54 azacitidine 54 peginterferon alfa 2b 54 degarelix 54 intravitreal injection 54 mg iv peramivir 54 undetectable HCV RNA 54 ACTEMRA TM 54 gemcitabine chemotherapy 54 placebo 54 subcutaneous dose 54 forodesine 54 plus prednisone prednisolone 54 relapsed CLL 54 tobramycin inhalation solution 54 hypomagnesemia 54 PegIFN RBV 54 hours postdose 54 QTcF 54 efavirenz EFV 54 Median PFS 54 IFN alfa 54 valopicitabine 54 Navelbine 54 5mg/kg 54 ritonavir boosted atazanavir 54 Xeloda ® 54 mg dosed twice 54 q#d 54 octreotide LAR 54 6mg 54 mg dosed 54 #.#mg/kg [002] 54 5FU 54 5 fluorouracil 54 multicenter Phase 54 naïve HCV 54 plus dexamethasone 54 intravenous dose 54 Cmax 54 ZALBIN dosed 54 topotecan 54 inhalations twice 54 Pegasys peginterferon alfa 2a 54 pemetrexed 54 capecitabine 54 dose cytarabine 54 mg mL 54 ACR# response 54 #/#.# mcg 54 oral levofloxacin 54 mg kg intravenously 54 PegIFN 54 hour bronchodilation 54 #.#mg/dL 54 chemotherapy docetaxel 54 plus gemcitabine 54 paclitaxel cisplatin 54 flutamide 53 rizatriptan 53 tumor progression TTP 53 cisplatin 53 ara C 53 FOLPI regimen 53 ng mL 53 gemcitabine cisplatin 53 DOXIL 53 mcg kg min 53 patients receiving ERBITUX 53 dose dexamethasone 53 azathioprine monotherapy 53 placebo controlled Phase 53 HBeAg seroconversion 53 Acetate Rectal Suppositories 53 Fludara 53 amoxicillin clavulanate 53 q# 53 PREZISTA rtv 53 daily Infergen 53 mcg QD 53 bortezomib refractory 53 evaluable subjects 53 μg mL 53 dosed orally 53 epoetin alfa 53 gemcitabine Gemzar ® 53 Taxotere R 53 ALIMTA 53 blinded randomized placebo controlled 53 virologic failure 53 #mg #mg #mg [003] 53 REBETOL 53 #μg [002] 53 mapatumumab 53 uM 53 pomalidomide 53 rituximab 53 subcutaneous SC 53 pmol L 53 amprenavir 53 cyclophosphamide doxorubicin vincristine 53 Psoriasis Area 53 underwent surgical resection 53 oral ribavirin 53 dosing regimens 53 cytarabine 53 dosing schedules 53 gemcitabine carboplatin 53 leuprorelin 53 randomized #:# 53 imetelstat 53 PEGASYS ® 53 milligrams mg 53 dose colchicine 53 lenalidomide 53 dexamethasone 53 leucovorin 53 postdose 53 plasma uric acid 53 dosing 53 FOLFIRI alone 53 ug dose 53 kilogram mg kg 53 darbepoetin alfa 53 TAXOTERE R 53 weekly subcutaneous injections 53 mg subcutaneous 53 mg/# h 53 peg interferon 53 Chemophase 53 IU mL 53 receiving VICTRELIS 53 free survival PFS 53 paclitaxel chemotherapy 53 anthracycline taxane 53 intradermal injections 53 Hemopurifier ® treatments 53 microg 53 hematologic toxicity 53 copies mL 53 fallopian tube carcinoma 53 epirubicin cyclophosphamide 52 pegylated liposomal doxorubicin 52 zonisamide SR 52 ng dL 52 trastuzumab Herceptin R 52 rFSH 52 relapsed MM 52 bendamustine 52 μg doses 52 peginterferon alfa 2a #KD 52 bevacizumab 52 Engerix B 52 desvenlafaxine succinate 52 subcutaneously administered 52 SVR# 52 EUFLEXXA R 52 budesonide pMDI 52 #mg [001] 52 metastatic colorectal carcinoma 52 bortezomib Velcade R 52 mg Lucentis 52 #.#g/day 52 cisplatin gemcitabine 52 postoperative chemotherapy 52 log# IU mL 52 COZAAR 52 CCyR 52 thrombocytopenia 52 mL kg 52 dasatinib Sprycel ® 52 alpha 2a 52 log# reduction 52 RECIST criteria 52 ug mL 52 nM 52 dexamethasone Decadron 52 papillary renal cell carcinoma 52 plasma HCV RNA 52 certolizumab pegol 52 zoledronic acid 52 #mg doses [002] 52 liposomal doxorubicin 52 oxycodone CR 52 alanine aminotransferase 52 abiraterone acetate 52 low dose cytarabine 52 safety tolerability pharmacokinetics 52 aspartate aminotransferase 52 mEq L 52 fluoropyrimidine 52 ALT normalization 52 melphalan prednisone 52 amphotericin B 52 sunitinib 52 ABC/3TC 52 HIV RNA 52 stage IIIB 52 subcutaneous enoxaparin 52 Bezielle 52 achieved CCyR 52 discontinuations due 52 IXEMPRA 52 metastatic hormone refractory 52 aminotransferase elevations greater 52 intravenous dosing 52 mg q#h 52 deferoxamine 52 mg kg REMICADE 52 ABVD 52 subcutaneous infusion 52 tipranavir r 52 #mg dose [003] 52 chemoradiation therapy 52 DAVANAT 52 placebo dexamethasone 52 GnRH agonist 52 Jevtana 52 receiving highly emetogenic 52 oral clodronate 52 mu g 52 GEMZAR 52 MBq 52 Pemetrexed 52 dose escalation trial 52 temsirolimus 52 cisplatin vinorelbine 52 mycophenolate mofetil 52 cyclophosphamide chemotherapy 52 Gy 52 ≥ 52 hypophosphatemia 52 refractory multiple myeloma 52 dosing intervals 52 cyclophosphamide AC 52 EMEND 52 undetectable virus HCV 52 Peginterferon 52 visilizumab 52 CLL SLL 52 HCV SPRINT 52 aspirin heparin 52 treatment naïve genotype 52 Copegus ribavirin 52 elotuzumab 52 mg tid 52 pegylated interferon alpha 52 IIIa inhibitor 52 infliximab monotherapy 52 FUSILEV enhances 52 low dose dexamethasone 52 remission induction 52 postmenopausal osteoporotic women 52 busulfan 52 Randomized Phase 52 paclitaxel Taxol R 52 PEG Interferon lambda 52 sustained virologic response 52 sorafenib Nexavar 52 triamcinolone 52 docetaxel Taxotere ® 52 Flu Cy 52 glufosfamide 51 irbesartan 51 FOLFOX regimen 51 cell lymphoma CTCL 51 patients evaluable 51 lumbar spine BMD 51 1mg 51 oral rivaroxaban 51 gout flares 51 paclitaxel poliglumex 51 fasting plasma glucose FPG 51 nucleoside naive 51 HGS ETR2 51 BENICAR 51 mEq 51 adefovir 51 tirofiban 51 paclitaxel Taxol ® 51 timepoint 51 SPRYCEL 51 paclitaxel Taxol 51 iobenguane 51 Median progression 51 lymphoid blast 51 sorafenib tablets 51 BARACLUDE ® 51 HCV RESPOND 2 51 PEGINTRON TM 51 edoxaban 51 PREZISTA r arm 51 dasatinib 51 infliximab 51 unfractionated heparin 51 SCH # 51 insulin detemir 51 null responder HCV 51 acute gout flares 51 paclitaxel 51 p = NS 51 GSK# [001] 51 pulmonary exacerbations 51 VAPRISOL 51 5 FU leucovorin 51 interferon ribavirin 51 potent CYP#A# inhibitors 51 ABRAXANE therapy 51 enoxaparin 51 stage IIIb IV 51 6 mercaptopurine 51 Peginterferon Alfa 2a 51 COPEGUS 51 mg FV 51 Doxil ® 51 weekly intravenous infusions 51 dapagliflozin plus 51 neoadjuvant 51 mM 51 AEGR 51 pegylated interferon peg IFN 51 CR CRu 51 PEG Intron ® 51 vancomycin 51 ropivacaine 51 pamidronate 51 placebo PBO 51 etanercept 51 Pharmacokinetic parameters 51 HGS ETR1 51 CRp 51 ISTODAX 51 mg BID dose 51 cEVR 51 ALT elevations 51 carmustine 51 NATRECOR R 51 cisplatin chemotherapy 51 ng ml 51 achieved sustained virologic 51 Telintra 51 μg ml 51 plus glycoprotein IIb 51 Alkeran 51 dosed 51 tolterodine ER 51 serum phosphorus 51 dosage regimens 51 pegylated interferon alpha 2a 51 pegylated interferon 51 highly emetogenic 51 docetaxel Taxotere 51 OADs 51 Omacetaxine mepesuccinate 51 Neulasta ® 51 Elotuzumab 51 pyrazinamide 51 Dose escalation 51 composite endpoint 51 5 fluorouracil leucovorin 51 Panzem R NCD 51 azacytidine 51 #mg ATC 51 HBeAg positive patients 51 Response Evaluation Criteria 51 temozolomide 51 TMC# [001] 51 PSMA ADC 51 concurrent chemoradiation 51 heavily pretreated patients 51 voriconazole 51 titrated glipizide 51 trastuzumab 51 Taxotere 51 dose regimen 51 TTF Therapy 51 Ceplene/IL-2 51 ertapenem 51 mIU mL 51 insulin glulisine 51 LEXIVA 51 endoscopic remission 51 receiving prophylactic anticoagulation 51 plasma concentrations 51 ZYVOX 51 neoadjuvant chemotherapy 51 neurologic progression 51 doxorubicin docetaxel 51 serum urate 51 mmol L 50 leukopenia 50 insulin degludec 50 ixabepilone 50 nelfinavir 50 CDAI 50 cells/mm3 50 NATRECOR ® 50 paclitaxel carboplatin 50 x ULN 50 peginterferon 50 PROMACTA 50 subcutaneous injection 50 Taxotere ® 50 granisetron 50 CLARITY study 50 PEG Interferon alfa 50 plus GP IIb 50 P = .# 50 FluCAM 50 biologic DMARD 50 fluticasone salmeterol 50 MGd 50 rhEPO 50 iniparib BSI 50 -#.# mg dL [002] 50 receiving INTRON 50 Carboplatin 50 #mg doses [001] 50 maximal dose 50 1mg 2mg 50 Toxicities 50 Camptosar ® 50 Solid Tumors criteria 50 chemoradiotherapy 50 generalized edema 50 doxorubicin 50 dose escalation study 50 baseline LDH 50 2mg 50 -#.# log# copies mL 50 G CSF 50 diuretic chlorthalidone 50 maximal tolerated 50 neutropenia dehydration dyspnea 50 apremilast 50 neutropenia 50 pmol liter 50 hypercalcemia 50 epoetin alpha 50 Elitek 50 ceftriaxone 50 dosing regimen 50 PRADAXA 50 sunitinib malate 50 BENICAR HCT 50 cells μL 50 TORISEL 50 randomized 50 fluticasone furoate 50 mesalamine granules 50 dose titration 50 bolus dose 50 pegIFN 50 milligram doses 50 inhaled fluticasone 50 Index CDAI score 50 refractory CLL 50 randomization 50 eribulin mesylate 50 placebo p 50 Hypomagnesemia occurred 50 unresectable Stage III 50 PegIntron 50 serum concentrations 50 ARCOXIA 50 hematologic toxicities 50 beclomethasone dipropionate 50 KOMBIGLYZE XR 50 Gemcitabine 50 tapentadol ER 50 STELARA 50 mU liter 50 ZACTIMA 50 double blinded placebo 50 Phase 1b 50 vincristine doxorubicin 50 p = #.# [004] 50 cefazolin 50 metastatic GIST 50 Ixempra 50 ml min 50 Index CDAI 50 LIALDA 50 serum potassium 50 -#.# log# 50 neoadjuvant treatment 50 CRESTOR #mg 50 ganciclovir 50 HER2 positive metastatic breast 50 chronic HCV genotype 50 non inferiority 50 fludarabine 50 R# #mg BID 50 urinary N telopeptide 50 recurrent genital herpes 50 nadolol 50 NovoLog ® Mix 50 RECIST Response Evaluation Criteria 50 tacrolimus ointment 50 bupivacaine 50 chemo radiotherapy 50 recurrent glioblastoma multiforme 50 Zometa hazard 50 HCV genotype 50 Gliadel Wafer 50 oral deforolimus 50 RNA copies mL 50 ethambutol 50 relapsed multiple myeloma 50 interferon alfa 2b 50 maximally tolerated dose 50 achieved statistical significance 50 nucleoside analog 50 dosing interval 50 FluCAM arm 50 Contrave# 50 dosage regimen 50 mmol kg 50 steroid dexamethasone 50 goserelin 50 cells uL 50 prospectively randomized 50 peginterferon alpha 2a 50 mg p = 50 azilsartan medoxomil 50 PEG Intron 50 PRECiSE 50 cetuximab 50 adefovir treated 50 sUA 50 HYZAAR 50 IFN α 50 Mg Usa 50 urate lowering therapy 50 zoledronate 50 adjunctive placebo 50 HBeAg negative patients 50 prior chemotherapy regimens 50 evaluating tivozanib 50 erlotinib Tarceva ® 50 g dl 50 androgen suppression 50 vinca alkaloid 50 Paraplatin ® 50 Lupuzor ™ 50 5 FU 50 ug ml 50 virologic breakthrough 50 teriflunomide 50 millisieverts mSv 50 celgosivir 50 Platinol 50 BRIM2 50 ipsilateral breast 50 Aptivus ® 50 Pharmacokinetics PK 50 beta2 agonist 50 undetectable viral 50 mesalamine 50 golimumab CNTO 50 intravenously administered 50 insulin glargine 50 triptorelin 50 COMBIVIR 50 dose escalation phase 50 plus COPEGUS 50 9mg 50 aflibercept 50 creatinine clearance 50 mitoxantrone chemotherapy 50 virologic response EVR 49 baseline FEV 49 pg ml 49 Peginterferon alfa 2b 49 laboratory abnormalities 49 #mg dose [002] 49 placebo controlled dose escalation 49 PRADAXA #mg 49 Platinol ® 49 pegylated interferon alfa 49 sorafenib Nexavar ® 49 ribavirin therapy 49 unblinded 49 formoterol fumarate 49 serum HBV DNA 49 Pegylated Interferon 49 mg/# mg twice 49 isoproterenol 49 DOXIL ® 49 nasopharyngitis 49 ULORIC 49 remifentanil 49 zidovudine 49 CR nPR 49 mL 49 #.#mg [004] 49 ritonavir boosted lopinavir 49 albinterferon alfa 2b 49 mg calcium 49 Durezol 49 pfu 49 blood Phe 49 Decitabine 49 % Confidence Interval 49 Single Dose 49 lanthanum carbonate 49 valacyclovir 49 mg niacin 49 Traficet EN 49 μM 49 milatuzumab 49 mg kg ip 49 atazanavir 49 baminercept 49 EBRT 49 transdermal estradiol 49 COLAZAL ® 49 oral ridaforolimus 49 urate lowering 49 ng dl 49 nicardipine 49 #mg [002] 49 TMC# r 49 AUC0 49 MIC# [001] 49 medroxyprogesterone acetate 49 huN# DM1 49 chemoradiation 49 Free Survival PFS 49 zolmitriptan 49 μSv 49 FIRMAGON 49 BROVANA 49 alefacept 49 YERVOY 49 chemotherapy regimens 49 platinum refractory 49 annualized relapse 49 bronchodilation 49 metastatic CRC 49 placebo capsules 49 infusional 49 MAGE A3 ASCI 49 kg -1 49 PEGINTRON 49 partial remissions 49 evaluating REVLIMID 49 leukemia AML 49 adjuvant cisplatin 49 tinzaparin 49 XELOX 49 pyrimidine nucleoside analog 49 mL min 49 bleomycin 49 lamivudine 49 thymalfasin 49 glulisine 49 null responders 49 Irinotecan 49 recurrent metastatic 49 fosamprenavir 49 mg dL 49 PSA nadir 49 Viread Emtriva 49 doxorubicin HCl liposome injection 49 urinary sodium excretion 49 mg kg belimumab 49 primary hypercholesterolemia 49 oral prednisolone 49 peginterferon alfa 49 corticosteroid dose 49 clopidogrel 49 chemotherapy regimen 49 EGFR TKI 49 noninferior 49 HCV RNA 49 alkylating agent 49 corticosteroid dexamethasone 49 Topotecan 49 VICTRELIS 49 pharmacologically active isomer 49 cilengitide 49 Ribavirin 49 randomized #:#:# 49 events AEs 49 nadroparin 49 IEQ kg 49 Vincristine 49 timolol 49 neratinib 49 min -1 49 lopinavir ritonavir plus 49 mitomycin C 49 Hycamtin ® 49 PROCTOCORT ® Suppository Hydrocortisone 49 alfa 2b 49 ofatumumab 49 nmol 49 glatiramer acetate 49 Xcytrin 49 budesonide formoterol 49 abciximab 49 hypofractionated 49 postintervention 49 4mg 49 splenectomized patients 49 REVLIMID lenalidomide 49 luteinizing hormone releasing 49 binary restenosis 49 fallopian tube cancers 49 aspartate aminotransferase AST 49 infusional 5-FU/LV 49 receiving PEGINTRON 49 Cytoxan 49 salmeterol fluticasone 49 antithymocyte globulin 49 cisplatin carboplatin 49 IIIa inhibitors 49 #ug [002] 49 nevirapine NVP 49 #mg/#mg 49 placebo controlled clinical trials 49 non splenectomized 49 cis retinoic acid 49 fatigue asthenia 49 intratumoral 49 Crohn Disease Activity 49 MVax 49 intravenous IV infusion 49 CIMZIA TM certolizumab pegol 49 ibandronate 49 heavily pretreated 49 detectable HCV RNA 49 leucopenia 49 gastric pH 49 blinded randomized 49 ELOXATIN 49 HBeAg negative 49 preoperative chemotherapy 49 Cutaneous T 49 Mg Uk 49 bolus injection 49 relapsing multiple sclerosis 49 vincristine 49 Orally administered 49 lopinavir ritonavir Kaletra 49 HALAVEN 49 tocilizumab 49 Allovectin 7 ® 49 refractory AML 49 multicenter Phase III 49 nasal spray inhaled 49 advanced hepatocellular carcinoma 49 LAB GHRH 49 imatinib therapy 49 intramuscular dose 49 cetuximab Erbitux R 49 AZT zidovudine Retrovir 49 vitamin D2 49 Gemzar ® 49 CTAP# Capsules 49 Retreatment 49 definite stent thrombosis 49 unfractionated heparin UFH 49 tolvaptan 49 postoperatively 49 mol L 49 pegfilgrastim 49 Laquinimod 49 Seliciclib 49 dalteparin 49 phase Ib 49 primary efficacy endpoint 49 Neoadjuvant 48 interquartile range 48 miconazole 48 ^ sup 48 imatinib 48 ximelagatran 48 dose proportional pharmacokinetics 48 ORENCIA 48 lamivudine 3TC 48 Secondary endpoints include